Literature DB >> 16837491

Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan.

T Yamada1, A Nakajima, E Inoue, E Tanaka, M Hara, T Tomatsu, N Kamatani, H Yamanaka.   

Abstract

OBJECTIVE: To determine the risk for tuberculosis infection in patients with rheumatoid arthritis before the anti-cytokine era in Japan. PATIENTS AND METHODS: A database of a single-institute-based large observational cohort study for rheumatoid arthritis at the Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, was analysed. Information on the history of tuberculosis infection was collected by patient self-reporting during April and October 2003. The age-adjusted incidence rate and relative risk for tuberculosis infection were investigated.
RESULTS: Among 5044 patients with rheumatoid arthritis, 483 (9.6%) patients claimed to have a history of tuberculosis infection before October 2002. The frequency of history of tuberculosis increased according to the age of the patient. Four cases of new-onset tuberculosis were identified among 5544 patients with rheumatoid arthritis during 1 year. The age-adjusted incidence of tuberculosis was 42.4/100,000 patients. The relative risk for tuberculosis was 3.21 (95% confidence interval (CI) 1.21 to 8.55), and that of men and women was 10.59 (95% CI 3.42 to 32.78) and 1.41 (95% CI 0.2 to 10), respectively.
CONCLUSION: There was an increased risk of tuberculosis infection in Japanese patients with rheumatoid arthritis, especially in male patients before the introduction of anti-tumour necrosis factor treatment. These data should form the basis for the risk management of anti-cytokine treatment in Japan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837491      PMCID: PMC1798455          DOI: 10.1136/ard.2005.047274

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

3.  Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Authors:  Loreto Carmona; Juan J Gómez-Reino; Vicente Rodríguez-Valverde; Dolores Montero; Eliseo Pascual-Gómez; Emilio Martin Mola; Luis Carreño; Manuel Figueroa
Journal:  Arthritis Rheum       Date:  2005-06

4.  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Authors:  Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Victoria Romanus; Lars Klareskog; Nils Feltelius
Journal:  Arthritis Rheum       Date:  2005-07

Review 5.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

Review 6.  What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

Authors:  Michael H Weisman
Journal:  J Rheumatol Suppl       Date:  2002-09

7.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Furst; M H Weisman; E W St Clair; G F Keenan; D van der Heijde; P A Marsters; P E Lipsky
Journal:  Arthritis Rheum       Date:  2004-04

8.  Increased risk of tuberculosis in patients with rheumatoid arthritis.

Authors:  Loreto Carmona; César Hernández-García; Cristina Vadillo; Esperanza Pato; Alejandro Balsa; Isidoro González-Alvaro; Miguel Angel Belmonte; Xavier Tena; Raimon Sanmartí
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

9.  Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

Authors:  Frederick Wolfe; Kaleb Michaud; Janice Anderson; Kathy Urbansky
Journal:  Arthritis Rheum       Date:  2004-02

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
  10 in total
  17 in total

1.  Incidence of malignancy in Japanese patients with rheumatoid arthritis.

Authors:  Toru Yamada; Ayako Nakajima; Eisuke Inoue; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

2.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

3.  Heterozygote genotypes for PADI4_89 were protectively associated with susceptibility to tuberculosis in Koreans.

Authors:  Mi-Kyoung Lim; Tae Sun Shim; Mira Park; Soo-Kon Lee; Yong-Hak Sohn; Dong-Hyuk Sheen; Seung-Cheol Shim
Journal:  Rheumatol Int       Date:  2014-09-10       Impact factor: 2.631

4.  Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study.

Authors:  Takefumi Furuya; Shigeru Kotake; Eisuke Inoue; Yuki Nanke; Toru Yago; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani; Hisashi Yamanaka
Journal:  J Bone Miner Metab       Date:  2008-08-30       Impact factor: 2.626

5.  Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis.

Authors:  Shunsuke Mori; Hiromichi Naito; Sumire Ohtani; Tohru Yamanaka; Mineharu Sugimoto
Journal:  Clin Rheumatol       Date:  2008-11-11       Impact factor: 2.980

6.  Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Authors:  Filip De Keyser
Journal:  Curr Rheumatol Rev       Date:  2011-02

7.  Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany.

Authors:  Christian Gutsfeld; Ioana D Olaru; Oliver Vollrath; Christoph Lange
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

8.  One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.

Authors:  Chong-Hong Lim; Ching-Heng Lin; Der-Yuan Chen; Yi-Ming Chen; Wen-Cheng Chao; Tsai-Ling Liao; Hsin-Hua Chen
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

9.  Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.

Authors:  Shweta Agarwal; Siddharth Kumar Das; Girdhar G Agarwal; Ragini Srivastava
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-02-24

10.  Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.

Authors:  Tsai-Ling Liao; Ching-Heng Lin; Yi-Ming Chen; Chia-Li Chang; Hsin-Hua Chen; Der-Yuan Chen
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.